POLAREAN IMAGING PLC

Capital/Financing Update • Sep 25, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5457N

Polarean Imaging PLC

25 September 2019

Polarean Imaging Plc 

("Polarean" or the "Company")

Polarean notes statement from Amphion Innovations

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender"). 

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020.  No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries: 

Polarean Imaging plc			www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer				Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP				Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR	Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Paul McManus		Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEAANLAALNEAF